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Background. The therapeutic goal of antiretroviral therapy (ART) is sustained immune recovery and viral suppression. 
However, some patients experience poor CD4 cell count responses despite achieving viral suppression. Such discordant immune 
responses have been associated with poor clinical outcomes. 
Objective. We aimed to determine the prevalence of discordant immune response and explore associated factors in a 
retrospective cohort of patients attending 2 large public sector clinics, during the 6 months following ART initiation. 
Methods. Data were analysed from 810 HIV-infected adults initiated on first-line HAART at 2 clinics in Johannesburg, between 
1 November 2008 and 31 December 2009. Multivariate logistic regression models were used to estimate adjusted odds ratios 
(AORs) to determine associations between discordant immune response and clinical and demographic factors. 
Results. At ART initiation, 65% (n=592) of participants were female, with a mean age of 38.5 years. Median baseline CD4 
cell count was 155 cells/mm3, 70% (n=645) of patients had a haemoglobin level >11 g/dl and 88% (n=803) were initiated on 
stavudine-lamivudine-efavirenz/nevirapine (D4T-3TC-EFV/NVP). Six months after ART initiation, 24% (n=220) of patients 
had a discordant immune response and 7% (n=67) a discordant virological response. On multivariate analysis, baseline CD cell 
count ≥200 cells/mm3 (AOR 3.02; 95% confidence interval (CI) 2.08 - 4.38; p<0.001) and moderate anaemia (8.0 - 9.4 g/dl) at 
baseline (AOR 2.30; 95% CI 1.25 - 4.59; p=0.007) were independently associated with the development of discordant immune 
response, after adjustment for education level, World Health Organization (WHO) clinical stage and ART regimen. 
Conclusions. Discordant immune response following ART initiation was common and associated with baseline anaemia and 
CD4 cell count in our cohort. Intensive monitoring of at-risk individuals may improve clinical outcomes. 
S Afr J HIV Med 2012;13(4):168-172. DOI:10.7196/SAJHIVMED.861
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HIV infection is typically associated 
with progressive CD4 cell depletion and 
consequent immunodeficiency.1-3 The 
introduction of antiretroviral therapy 
(ART) has seen a decline in the morbidity 
and mortality associated with HIV 
infection.4 This is a consequence of the 
ability of ART to suppress HIV viraemia 
to undetectable levels and allow immune 
restoration, resulting in an increase in 
circulating CD4 cells.5  In clinical practice, 
however, not all patients receiving ART 










achieve the desired concordant response 
of viral suppression with CD4 cell count 
increase.6 As many as 20 - 40% of patients 
on ART do not show a significant increase 
in CD4 cell count despite viral suppression.6 
This phenomenon is referred to as discordant 
immune response and is associated with an 
increased risk of developing an AIDS event or 
death.6-9 
Discordant immune response may 
arise either as a result of failed immune 
reconstitution or the excessive destruction of 
CD4 cells.10 The reconstitution of peripheral 
CD4 cells is a biphasic process with an 
initial rapid increase of memory CD4 cells, 
succeeded by a slow increase in naive CD4 
cells.11,12 The second rise in CD4 cells may 
be due to cellular expansion or sustained cell 
survival in the periphery, as well as the central 
regeneration of cells by the thymus.10
Despite the relative frequency of discordant 
immune response following ART initiation, 
data on the prevalence of this phenomenen 
and associated factors are still limited in South 
Africa (SA), as well as in other low- and 
middle-income countries, where treatment 
is primarily nucleoside reverse transcriptase 
inhibitor (NRTI)-based.13 In these settings 
patients often initiate treatment at advanced 
stages of immunosuppression and have 
co-morbidities that compromise treatment 
response.14 The lack of knowledge about 
this subgroup may contribute to inadequate 
clinical management, as current HIV 
treatment guidelines do not provide specific 
applicable guidance. In this retrospective 
study we describe the prevalence of, and 
factors associated with, discordant immune 
response in a cohort of patients from 2 large 
public sector clinics in SA in the first 6 months 
after ART initiation. 
Methods
We retrospectively analysed data from 810 
HIV-infected patients aged >16 years who 
initiated ART at 2 district comprehensive 
care management and treatment centres 
in Ekurhuleni, Gauteng Province, from 
1 November 2008 to 31 December 2009. 
Ekurhuleni, the largest district in the province, 
has a population of nearly 3 million people, 
and an HIV prevalence of 31.5%.15 Patients 
were included in the study if they were ART-
naive at the time of treatment initiation, and 
were maintained on a standard first-line ART 
regimen16 for at least 3 months following 
treatment initiation. 
Ethical approval and study permission 
were obtained from the Human Research 
Ethics Committee of the University of the 
Witwatersrand and the Ekurhuleni Ethical 
Panel.
Data collection
Patient demographics and contact information 
were recorded at the commencement visit 
to the clinic. At ensuing visits, the patients’ 
weight, reports of any symptoms and new 
diagnoses were recorded. Data were collated 
by trained data capturers after each visit. 
Results of CD4 cell count, plasma HIV viral 
load (PVL), full blood count and liver function 
tests (LFTs) were recorded upon receipt. All 
data were maintained in the patient health 
management database Therapy-Edge. STATA 
software (version 11) was used for data 
analysis.
Socio-demographic characteristics (age, 
gender, education level, occupation status 
and alcohol use/smoking), medical history 
including prior pulmonary tuberculosis (TB) 
and ART information were extracted from 
Therapy-Edge, as were physical examination 
findings such as body mass index (BMI), liver 
function and haemoglobin (Hb) values. Hb, 
LFTs and CD4 cell count were measured at 
ART initiation (i.e. baseline) and at 6 months 
post-ART initiation, with only PVL measured 
at 6 months. 
Outcome assessment 
Viral suppression was defined as a PVL <400 
copies/ml at 6 months after ART initiation.16 
Immune reconstitution was defined as an 
absolute increase in the CD4 cell count value 
of 50 cells/mm3 at an average of 6 months 
after ART initiation. A discordant immune 
response was defined as a failure of immune 
reconstitution (increase in CD4 cell count 
<50 cells/mm3) within 3 - 6 months of ART 
initiation, in the presence of viral suppression 
(PVL <400 copies/ml). Measurements within 
3 - 6 months of ART initiation were used, 
in accordance with the 6-month follow-up 
recommended in national guidelines.16
Statistical methods
Descriptive statistics, using means and 
standard deviations for continuous variables, 
and frequencies for categorical variables, 
were used to report sample characteristics. 
Associations between the main outcome and 
potential explanatory factors were assessed 
using variate logistic regression, using odds 
ratios (ORs) and 95% confidence intervals 
(CIs) to express the measure of association. 
Factors that were significant at p≤0.2 in 
univariate analysis were considered for 
inclusion in multivariate logistic regression 
models. Final models were derived using 
forward selection and backward elimination 
techniques. The final model was adjusted for 
education level, World Health Organization 
(WHO) clinical stage, baseline CD4 cell count, 
and ART regimen, and adjusted ORs (AORs) 
were presented. Baseline WHO clinical stage 
was included in the final model regardless 
of statistical significance in the univariate 
analysis because of the link between HIV 
clinical disease and outcome. These models 
were tested using the Hosmer-Lemeshow 
goodness-of-fit test. Interactions between all 
significant variables in the model were also 
investigated. Collinearity was tested in all 
the regression models. A sensitivity analysis 
to demonstrate the robustness of the study 
findings to variation in definition of CD4 cell 
count response was also conducted using a 
30% increase from baseline CD4 cell count as 
the desired response.
Results
A total of 6 460 adults enrolled in the ART 
programme at the 2 clinics; 4 581 (80%) 
were excluded due to an absent baseline/6-
month follow-up CD4 cell count and/or 
PVL, and a further 962 were excluded due 
to a lack of additional information (e.g. ART 
regimen or baseline laboratory values). Of 
the remaining 917 eligible, 810 were included 
for analysis. The remainder were excluded 
as they had discordant virological responses 
(i.e. immune reconstitution in the absence of 
viral suppression) or were non-responders (no 
change in CD4 cell count or PVL). 
Prevalence of discordant 
immune response on ART
Within the cohort, 220 (24%) experienced a 
discordant immune response within 6 months 
of ART initiation. At baseline, the mean CD4 
cell count in the discordant group was 218 
cells/mm3 (SD ±168), compared with 137 cells/
mm3 (SD ±85) in the group with a concordant 
response to treatment. 
Factors associated with 
a discordant immune 
response 
Baseline characteristics of discordant and 
concordant immune responders were 












Table 1. Cohort characteristics with logistic regression analysis of factors associated with discordant v.  





n (%)*  OR (95% CI) p-value‡ AOR (95% CI) p-value‡





















1.91 (1.14 - 3.20) 
0.78 (0.29 - 2.15) 
0.014 
0.639 








2.90 (2.08 - 4.03) 0.0001 
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2.12 (0.56 - 7.98) 





Mild anaemia (9.5 - 10.9)











0.76 (0.49 - 1.19) 
1.55 (0.90 - 2.68) 





0.88 (0.54 - 1.45) 
2.30 (1.26 - 4.19) 






























1.11 (0.73 - 1.67) 0.630 
BMI
Normal (18.50 - 24.99)
Underweight (<18.50)











0.94 (0.50 - 1.79) 
0.58 (0.37 - 0.91) 



























0.48 (0.18 - 1.24) 
0.49 (0.20 - 1.19) 





















0.83 (0.40 - 1.71) 0.605 
ART = antiretroviral therapy; D4T = stavudine; 3TC = lamivudine; EFV/NVP = evafirenz/nevaripine; AZT = zidovudine; TDF = tenofovir; WHO = World Health Organization; Hb = 
haemoglobin; TB = tuberculosis; BMI = body mass index; ALT = alanine aminotransferase; AST = aspartate transaminase.
*Data are expressed as n (%) for categorical variables and mean (±SD) for continuous variables.
†Missing values. 
‡p-values were obtained using χ2 test and Student’s t-test. 










compared (Table 1). Compared with 
concordant immune responders, patients with 
discordant immune responses were more likely 
to be older, to have initiated ART at a higher 
baseline CD4 cell count, to have been initiated 
onto zidovudine or tenofovir-containing ART 
regimens, and to have significantly different 
Hb levels and moderate anaemia at the start of 
ART. No significant differences were observed 
between the groups in terms of gender, 
occupational status, education level, history 
of tuberculosis, smoking or alcohol use, BMI, 
WHO clinical stage, or aspartate transaminase 
(AST) and alanine transaminase (ALT) levels.
In the final model, a discordant immune 
response was found to be associated with 
increasing age (AOR 1.02; CI 1.00 - 1.04; 
p=0.031), initiating treatment at a CD4 
cell count >200 cells/mm3 (AOR 3.02; CI 
2.08 - 4.38; p<0.0001), and the presence of 
moderate anaemia (Hb 8.0 - 9.4 g/dl) (AOR 
2.3; CI 1.26 - 4.19; p=0.007), after adjusting 
for baseline education, WHO clinical stage, 
CD4 cell count and ART regimen (Table 
1). No significant interactions were found 
between the significant variables in the final 
model, which was deemed adequate using 
the Hosmer-Lemeshow goodness-of-fit test 
(p=0.416).
The results of the sensitivity analysis, 
conducted by considering a 30% increase 
from baseline CD4 cell count as the desired 
response, are summarised in Table 2. The 
univariate analysis produced similar findings 
to those in the primary analysis. Only baseline 
Hb level failed as a significant factor in the 
development of discordant response using the 
modified outcome definition.
Discussion
Despite an adequate virological response, 24% 
of patients did not achieve an adequate immune 
response at 6 months after ART initiation. 
Increasing age, initiating ART at a CD4 cell 
count >200 cells/mm3, and initiating ART 
with moderate anaemia were associated with 
failure to achieve optimal immune restoration. 
No associations between discordant immune 
response and gender, BMI or ART regimen 
were observed, although these were identified 
as risk factors in other studies.17,18
The findings concerning age were 
consistent with findings from other studies, 
where increasing age was associated with poor 
immune recovery.5 In the North American 
AIDS Cohort Collaboration on Research 
Design (NA-ACCORD) study, data from 19 
cohorts and 12  196 participants showed that 
increasing age was associated with a lower 
chance of achieving an increase in CD4 cell 
count >100 cells/mm3 at 24 months following 
ART initiation.19 This has been linked to the 
observation that thymus activity, which is 
largely responsible for immune restoration, 
decreases with ageing.10
The literature is conflicting regarding 
the association of baseline CD4 cell count 
with discordant immune response outcome. 
Findings similar to ours emerged from a 
cohort of 4  810 patients initiating ART in 
the Antiretroviral Therapy in Low-Income 
Countries (ART-LINC) study.20 The 
association between ART initiation with 
a baseline CD4 cell count >200 cells/mm3 
and the development of discordant immune 
response can be explained by the nonlinear 
nature of CD4 cell count increases after ART 
initiation across the different baseline CD4 
cell count strata:4 starting treatment at higher 
CD4 cell counts limits the scope for further 
increases.21 These findings are important as 
treatment programmes increase the CD4 cell 
count threshold for ART initiation.
In contrast to our findings, several studies 
conducted in resource-rich settings have 
shown that low baseline CD4 cell count is 
associated with discordant immune response.4 
This is biologically plausible given that a low 
nadir pre-treatment CD4 cell count is thought 
to be suggestive of more extensive depletion 
of CD4 cells in the gut-associated lymphoid 
tissue during acute HIV infection, and may 
be delayed or refractory to reconstitution with 
ART.22 Genetic variability has been investigated 
as a possible modulator of immunological 
recovery, and may explain the divergent 
associations in the existing literature.
These data suggest that moderate anaemia 
at baseline is associated with failure to 
achieve immune recovery at 6-month 
follow-up – an association that has not been 
documented previously. The aetiology of 
anaemia in HIV infection is multifactorial, 
but is commonly due to underproduction 
of erythrocytes by the bone marrow stem 
cells.23 These stem cells are also responsible 
for the production of CD4 cells through the 
myeloid precursor cell.24 Poor production of 
myeloid precursor cells can therefore result in 
decreased production of both CD4 cells and 
erythrocytes. In addition, the erythrocytes 
of HIV-infected individuals may experience 
membrane changes which result in decreased 
pliability and premature destruction.25 The 
same applies to CD4 cells.25 These mechanisms 
of reduced stem cell activity and membrane 
changes could explain the association between 
anaemia when starting ART and a subsequent 
discordant immune response. However, this 
finding should be interpreted with caution, as 
it was not significant in the sensitivity analysis 
when the definition of immune response was 
altered. 
Study strengths and 
limitations
Although the sample size was relatively small, 
it was likely to be representative of patients in 
routine clinical care in Gauteng Province. The 
validity of the results may have been limited by 
the high proportion of missing data. Patterns 
in missing data could have resulted in non-
differential misclassification of patients, as 
a consequence of inaccurate measuring of 
outcomes and subsequent bias. However, such 
errors could have been evenly distributed 
among the groups and data were noted to 
be missing at random (analysis not shown). 
Table 2. Uni- and multivariate analysis for sensitivity of factors associated with discordant immune response 
at 6 months after ART initiation
OR (CI) p-value AOR (CI) p-value
Age (years) 1.02 (1.00 - 1.04) 0.0590 1.02 (1.00 - 1.04) 0.0300




5.51 (3.91 - 7.77) 0.0001
1
5.31 (3.71 - 7.61) 0.0001
OR = odds ratio; AOR = adjusted odds ratio; CI = confidence interval.












The outcomes were measured between 3 and 
6 months after ART initiation; it is therefore 
possible that factors associated with discordant 
immune response may have varied with longer 
periods of treatment. 
Conclusion
The findings of this study suggest that a 
significant proportion of patients initiating 
ART in SA do not achieve an optimal immune 
response after an average of 6 months on ART, 
despite virological suppression. Significant 
factors associated with the development of a 
discordant immune response were increasing 
age, baseline CD4 cell count >200 cells/mm3, and 
an Hb level of 8.0 - 9.4 g/dl. While further studies 
are required in local populations to examine 
these associations, these data may assist in the 
early identification of patients that are likely to 
have discordant immune responses on ART.
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